ranibizumab + placebo

This is a combination of ranibizumab, a recombinant humanized monoclonal antibody fragment that acts as an antagonist of vascular endothelial growth factor A (VEGF-A), and placebo, an inert substance with no therapeutic effect. Ranibizumab is used to treat several ocular conditions characterized by abnormal blood vessel growth and leakage in the eye, including neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization (mCNV), and macular edema following retinal vein occlusion. It works by binding to VEGF-A and inhibiting its activity, thereby reducing abnormal blood vessel formation and vascular permeability in the retina[1][2][3][4][5]. Placebo serves as a control in clinical trials to assess the efficacy and safety of ranibizumab.

Brand names

Lucentis

Other names

Lucentis plus placeboplacebo + ranibizumab-Santen Inc.-wet age-related macular degeneration